fda compounding rules

fda compounding rules

5 Secrets Prescription Weight Loss Pharmacies Must Know

As of July 1 2026 the FDA will remove semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, meaning pharmacies must revamp their processes or risk shutdown. The change targets weight-loss GLP-1 drugs and forces a shift to clinic-specific formulations, stricter labeling, and new traceability requirements. Medical Disclaimer: This